Sara Diaz-Diaz , Andrea Garcia-Montaner , Roberta Vanni , Marina Murillo-Torres , Esther Recacha , Marina R. Pulido , Maria Romero-Muñoz , Fernando Docobo-Pérez , Alvaro Pascual , Jose Manuel Rodriguez-Martinez
{"title":"临床分离的大肠埃希菌中 SOS 响应表达的异质性影响了对抗菌压力的适应性","authors":"Sara Diaz-Diaz , Andrea Garcia-Montaner , Roberta Vanni , Marina Murillo-Torres , Esther Recacha , Marina R. Pulido , Maria Romero-Muñoz , Fernando Docobo-Pérez , Alvaro Pascual , Jose Manuel Rodriguez-Martinez","doi":"10.1016/j.drup.2024.101087","DOIUrl":null,"url":null,"abstract":"<div><p>In recent years, new evidence has shown that the SOS response plays an important role in the response to antimicrobials, with involvement in the generation of clinical resistance. Here we evaluate the impact of heterogeneous expression of the SOS response in clinical isolates of <em>Escherichia coli</em> on response to the fluoroquinolone, ciprofloxacin. <em>In silico</em> analysis of whole genome sequencing data showed remarkable sequence conservation of the SOS response regulators, RecA and LexA. Despite the genetic homogeneity, our results revealed a marked differential heterogeneity in SOS response activation, both at population and single-cell level, among clinical isolates of <em>E. coli</em> in the presence of subinhibitory concentrations of ciprofloxacin. Four main stages of SOS response activation were identified and correlated with cell filamentation. Interestingly, there was a correlation between clinical isolates with higher expression of the SOS response and further progression to resistance. This heterogeneity in response to DNA damage repair (mediated by the SOS response) and induced by antimicrobial agents could be a new factor with implications for bacterial evolution and survival contributing to the generation of antimicrobial resistance.</p></div>","PeriodicalId":51022,"journal":{"name":"Drug Resistance Updates","volume":"75 ","pages":"Article 101087"},"PeriodicalIF":15.8000,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1368764624000451/pdfft?md5=d62973c9569c8b14b7be721203fa08fd&pid=1-s2.0-S1368764624000451-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Heterogeneity of SOS response expression in clinical isolates of Escherichia coli influences adaptation to antimicrobial stress\",\"authors\":\"Sara Diaz-Diaz , Andrea Garcia-Montaner , Roberta Vanni , Marina Murillo-Torres , Esther Recacha , Marina R. Pulido , Maria Romero-Muñoz , Fernando Docobo-Pérez , Alvaro Pascual , Jose Manuel Rodriguez-Martinez\",\"doi\":\"10.1016/j.drup.2024.101087\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>In recent years, new evidence has shown that the SOS response plays an important role in the response to antimicrobials, with involvement in the generation of clinical resistance. Here we evaluate the impact of heterogeneous expression of the SOS response in clinical isolates of <em>Escherichia coli</em> on response to the fluoroquinolone, ciprofloxacin. <em>In silico</em> analysis of whole genome sequencing data showed remarkable sequence conservation of the SOS response regulators, RecA and LexA. Despite the genetic homogeneity, our results revealed a marked differential heterogeneity in SOS response activation, both at population and single-cell level, among clinical isolates of <em>E. coli</em> in the presence of subinhibitory concentrations of ciprofloxacin. Four main stages of SOS response activation were identified and correlated with cell filamentation. Interestingly, there was a correlation between clinical isolates with higher expression of the SOS response and further progression to resistance. This heterogeneity in response to DNA damage repair (mediated by the SOS response) and induced by antimicrobial agents could be a new factor with implications for bacterial evolution and survival contributing to the generation of antimicrobial resistance.</p></div>\",\"PeriodicalId\":51022,\"journal\":{\"name\":\"Drug Resistance Updates\",\"volume\":\"75 \",\"pages\":\"Article 101087\"},\"PeriodicalIF\":15.8000,\"publicationDate\":\"2024-04-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1368764624000451/pdfft?md5=d62973c9569c8b14b7be721203fa08fd&pid=1-s2.0-S1368764624000451-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Resistance Updates\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1368764624000451\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Resistance Updates","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1368764624000451","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
近年来,新的证据表明,SOS 反应在抗菌药物反应中发挥着重要作用,并参与了临床耐药性的产生。在此,我们评估了大肠埃希菌临床分离株中 SOS 反应异质性表达对氟喹诺酮类药物环丙沙星反应的影响。对全基因组测序数据的硅学分析表明,SOS 响应调节因子 RecA 和 LexA 的序列具有显著的保守性。尽管基因具有同质性,但我们的研究结果表明,在亚抑制浓度环丙沙星的作用下,临床分离的大肠杆菌在群体和单细胞水平上的 SOS 反应激活具有明显的差异性。确定了 SOS 反应激活的四个主要阶段,并将其与细胞丝状化相关联。有趣的是,SOS 反应表达较高的临床分离株与耐药性的进一步发展之间存在相关性。这种由抗菌剂诱导的 DNA 损伤修复反应(由 SOS 反应介导)的异质性可能是对细菌进化和生存产生影响的一个新因素,有助于抗菌剂耐药性的产生。
Heterogeneity of SOS response expression in clinical isolates of Escherichia coli influences adaptation to antimicrobial stress
In recent years, new evidence has shown that the SOS response plays an important role in the response to antimicrobials, with involvement in the generation of clinical resistance. Here we evaluate the impact of heterogeneous expression of the SOS response in clinical isolates of Escherichia coli on response to the fluoroquinolone, ciprofloxacin. In silico analysis of whole genome sequencing data showed remarkable sequence conservation of the SOS response regulators, RecA and LexA. Despite the genetic homogeneity, our results revealed a marked differential heterogeneity in SOS response activation, both at population and single-cell level, among clinical isolates of E. coli in the presence of subinhibitory concentrations of ciprofloxacin. Four main stages of SOS response activation were identified and correlated with cell filamentation. Interestingly, there was a correlation between clinical isolates with higher expression of the SOS response and further progression to resistance. This heterogeneity in response to DNA damage repair (mediated by the SOS response) and induced by antimicrobial agents could be a new factor with implications for bacterial evolution and survival contributing to the generation of antimicrobial resistance.
期刊介绍:
Drug Resistance Updates serves as a platform for publishing original research, commentary, and expert reviews on significant advancements in drug resistance related to infectious diseases and cancer. It encompasses diverse disciplines such as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology, and clinical medicine. The journal addresses both basic research and clinical aspects of drug resistance, providing insights into novel drugs and strategies to overcome resistance. Original research articles are welcomed, and review articles are authored by leaders in the field by invitation.
Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective.
*Expert reviews in clinical and basic drug resistance research in oncology and infectious disease
*Describes emerging technologies and therapies, particularly those that overcome drug resistance
*Emphasises common themes in microbial and cancer research